Top of page Skip navigation
  • EARLY BIRD REGISTRATIONS EXTENDED

    Register before 18 August and save

  • RAISE YOUR ORGANISATIONS PROFILE

    Exhibitor packages available - reserve your space today

8.00 - 09.15

Registration, networking, breakfast and partnering

9.15 - 09.30

Welcome and BIA Update 

Steve Bates  OBE
Chief Executive Officer, BIA

9.30 - 09.50

Opening Keynote Presentation

Professor Sir John Bell
Regius Professor of Medicine, Oxford University

9.50 - 10.30

Alzheimer’s Research UK - Bridging the gap between academia and industry 

In this session, we’ll hear from experts on how charities can help progress research from academia towards drug discovery.  Dr David Reynolds, CSO, ARUK will lead this interactive panel discussion and explain how ARUK is helping to do this , the Interconnectivity with industry, addressing key gaps and progressing research towards patient benefit and citizen science and technology approaches to improving public understanding.  We’ll also address the need for further investment.

Chair
Dr David Reynolds
Chief Scientific Officer, Alzheimer's Research UK

Panel
Peter Atkinson 
Associate Director, Head of UK Open Innovation - Neurology Business Group, Eisai

Laurence Barker
Chief Business Officer - Dementia Discovery Fund, SV Health Investors   

John Davies 
Chief Scientific Officer, ARUK Drug Discovery Alliance

Andy Morris
Patient Advocate

10.30 - 11.00

BBSRC Innovator of the Year

11.00 - 11.30

 Refreshments, networking, exhibition and partnering

11.30 - 13.00

Parallel Tracks

11.30 - 12.15

Top considerations for protecting your innovations through IP

The legal landscape for protecting your IP is constantly changing. This session will equip you with the latest information you need to consider when designing your IP strategy.

We will be joined by Michael Tappin QC – who is widely acclaimed as one of the leading barristers for biotech and pharmaceuticals patent cases – to explain the implications of the recent UK Supreme Court ruling in Lilly vs Actavis, which introduced a new two-step process to determine if a patent infringes another due to equivalence.

A panel of experienced members of the BIA’s IP Advisory Committee will then discuss other recent developments in IP case law and upcoming policy developments that will impact BIA members’ ability to protect their innovations.

Keynote speaker
Michael Tappin QC

Chair
Nicola Baker-Munton
Chief Executive Officer, Stratage IPM

Speakers
Andrew Hutchinson
Partner, Simmons & Simmons 

Nicole Jadjea
Partner, Field Fisher 

Susie Middlemiss
Partner, Slaughter and May 

Gareth Morgan
Partner, CMS Cameron McKenna Nabarro Olswang 

 

Accelerating next generation medicines manufacturing

This session will discuss the advances in manufacturing of traditional biologics, next generation antibodies and cell and gene therapies, including the move from traditional centralised production models to smaller batches to deliver the precision medicines of the future.

Chair
Dr Kit Erlebach
Head of R&D Continuous Improvement, FUJIFILM Diosynth Biotechnologies 

Panel
Dr Jim Mills
Vice President Technical Operations, Abzena 

Dr Angela Osbourne
Managing Director, eXmoor Pharma Concepts 

Dr Jesus Zurdo
Senior Director Strategic Innovation, Lonza Biologics - confirmed

 

Cooperating to solve the key diagnostic challenges faced by the NHS

This session, led by Public Health England will look at some of the key diagnostic challenges faced by the NHS in a domestic as well as global health context. 

The UK is making great strides in diagnostic innovations – for example PHE has worked with universities, SMEs and big companies and filed patents in TB, Sepsis, etc. If these innovations are not evaluated and commercialised promptly, they will not benefit patients and the NHS will be left with major diagnostic challenges in key clinical areas.

Generating information on the clinical and cost-effectiveness of in vitro diagnostic devices is therefore very important to improve the way diseases are diagnosed. and will help patients access the most appropriate treatments more quickly, improve the lives of patients and help the NHS make the best use of its resources. It will also enable a better environment for life sciences and contribute to the UK’s economic growth, consistent with the Government’s Strategy for UK Life Sciences.

Chair

Nigel Silman
Senior Business Development Manager, Public Health England and Visiting Professor, University of West England

Speakers
Professor Paul Davis
Co-Founder and Chief Scientific Officer, Mologic and Honorary/Visiting Professor, Universities of Cardiff, Kent and Warwick

Angela Silmon
Chief Executive Officer, NewGene 

Professor Mark Wilcox
Consultant Microbiologist & Head of Microbiology, Leeds Teaching Hospitals, Professor of Medical Microbiology, University of Leeds and Lead on Clostridium difficile & Chairman of Rapid Review Panel, Public Health England 

Doris-Ann Williams MBE
Chief Executive, British in vitro Diagnostics Association 

 

12.15 - 13.00

Top considerations for protecting your innovations through IP continues

 

Developing and delivering Advanced Therapies – clinical trials are just the start 

This session will explore how to create and maintain value in the development chain for cell and gene therapies. Presenters will discuss how to use patents to secure the value of your product, ways to streamline your supply chain and how to obtain market access and reimbursement.

Chair
Dr Sven Kili

Vice President and Head of Cell and Gene Therapy Development, GlaxoSmithKline, and Chair of BIA’s Cell and Gene Therapy Advisory Committee

Speakers 
Dr Simon Ellison
Senior Manager, Advanced Therapies, Fisher BioServices

Dr Panos Kefalas
Head of Health Economics and Market Access, Cell and Gene Therapy Catapult

Dr Jennifer O’Farrell
Partner, Boult Wade

Cooperating to solve the  key diagnostic challenages faced by the NHS continues

13.00 - 14.15

Lunch, networking, exhibition and speed-partnering

14.15 - 15.45

Parallel Tracks

14.15 - 15.00

Moving from good to great - ensuring that the UK reamins an important location for early stage clinical trials

A key Regulatory strength in the UK is the openness of the MHRA to novel flexible and adaptive clinical trial design. In this session we will compare and contrast with the Regulatory Authorities in other countries, looking at addressing delays in the UK, and how this can be addressed, as well as what is delaying things in other countries, and how this can be avoided. In addition, a key logistical strength of the UK is the NHS. We will assess what can be further done to showcase this strength globally and consider the opportunities for improvement.

Chair
Dr Penny Ward
Chief Medical Officer, Karus Therapeutics 

Speakers
Dr Matthew Hallsworth
Head of External Relations, NIHR

Dr Ed Hodgkin
Partner, Syncona Partners
Sarah Kerruish
Chief Patient Officer, Antidote

Dr Vijay Reddy
Chief Medical Officer, Autolus 

Kirsty Wydenbach
Deputy Unit Manager and Senior Medical Assessor Clinical Trials Unit, MHRA 

Why the UK is a great place to do translational science

This session will explore the translational research landscape.  Our expert speakers will outline some aspects of the outstanding science-base represented by UK universities and institutions, and the opportunities that these present for translational research and their success in spinning-out companies based on discoveries arising from their academic research.  Following these two 15 minute presentations, both speakers and the chair will then open up the discussion with the audience

Chair
Dr Will West
Executive Chairman, CellCentric and BIA Board 

Speakers
Dr Veronique Birault
Head, Translational Science, The Francis Crick institute 

Prof Jim Huntingdon
Professor of Molecular Haemostasis, Cambridge University 

 

Leveraging UK investment and leadership in Genomics

More details to come

15.00 – 15.45

TBC

Maintaining investor and public confidence through good communications

Chair

Dr Chris Gardner
Partner, Consilium Strategic Communications

Sue Charles
Partner, Instinctif Partners Life Sciences

Charles Mayo
Partner, Simmons & Simmons

Next Generation Science

More details to come

 

 

15.45 - 16.15

Refreshments, networking, exhibition and speed-partnering

16.15 - 17.00

Sources of funding post Brexit

Panel discussion with

Steve Bates OBE
Chief Executive Officer, BIA

Jeremy Curnock Cook
Chairman, International Bioscience Managers

Alice Hu Wagner
Managing Director, Strategy Economics and Business Development

17.00 - 17.45

Brexit and Industrial Strategy

Panel discussion

17.45 - 17.50

Summary and Close

18.00 - 18.30

BIA AGM (BIA members Only)

18.30 - 21.00

BIA Autumn Reception - Connecting the bioscience community